JTE 052

Drug Profile

JTE 052

Alternative Names: JTE-052; JTE-052A

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Japan Tobacco
  • Class Antiallergics
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Autoimmune disorders; Hypersensitivity; Inflammation

Most Recent Events

  • 31 May 2017 Japan Tobacco initiates enrolment in a phase III trial for Atopic dermatitis in Japan before May 2017 (JapicCTI-173554)
  • 31 Mar 2017 Phase-II clinical trials in Atopic dermatitis (In children, In adolescents) in Japan (Topical) (JapicCTI173553)
  • 31 Mar 2017 Phase-III clinical trials in Atopic dermatitis in Japan (Topical) (JapicCTI-173555)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top